27 Result(s)
within
Paolo Antonio Ascierto
Oncology
-
Article
Open AccessImpact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma
Treatment duration with checkpoint inhibitors must be optimized to prevent unjustified toxicity, but evidence for the management of cutaneous squamous cell carcinoma is lacking. A retrospective study was perfo...
-
Article
Open AccessUpregulated expression of miR-4443 and miR-4488 in drug resistant melanomas promotes migratory and invasive phenotypes through downregulation of intermediate filament nestin
BRAF-mutant melanoma patients benefit from the combinatorial treatments with BRAF and MEK inhibitors. However, acquired drug resistance strongly limits the efficacy of these targeted therapies in time. Recentl...
-
Article
Open AccessMelanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps
Polymorphonuclear neutrophils (PMNs) are the main effector cells in the inflammatory response. The significance of PMN infiltration in the tumor microenvironment remains unclear. Metastatic melanoma is the mos...
-
Article
Open AccessSequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
The treatment strategy for BRAF-mutated melanoma remains unsatisfactory, although the advent of immune checkpoint inhibition has improved the prognosis of advanced melanoma. This article reports current evidence ...
-
Article
Open AccessThe clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic
COVID-19 pandemic following the outbreak in China and Western Europe, where it finally lost the momentum, is now devastating North and South America. It has not been identified the reason and the molecular mec...
-
Article
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients
Engineered cytokine products represent promising agents for the treatment of immunogenic tumors, such as malignant melanoma, in addition to immune checkpoint inhibitors. Here we describe the results of a contr...
-
Article
Open AccessGermline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study
Multiple primary melanomas (MPM) occur up to 8% of patients with cutaneous malignant melanoma (CMM). They are often sporadic harbouring several somatic mutations, but also familial cases harbouring a CDKN2A germl...
-
Article
Open AccessCorrection to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
Following publication of the original article [1], the author reported that an author name, Roberta Zappasodi, was missed in the authorship list.
-
Article
Open AccessToward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. The multifactorial d...
-
Article
Open AccessA multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Recent evidence suggested a potential correlation between overweight and the efficacy of immune checkpoint inhibitors (ICIs) in cancer patients.
-
Chapter
Melanoma
Melanoma is a malignant tumor that arises from melanocytic cells and primarily involves the skin. Early diagnosis is fundamental for surgical treatment of localized disease. A conservative surgical excision ap...
-
Article
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study
CTLA-4 blockade by means of ipilimumab (IPI) potentiates the immune response and improves overall survival (OS) in a minority of metastatic melanoma (MM) patients. We investigated the role of soluble CTLA-4 (s...
-
Article
Open AccessBaseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Previous studies have suggested that elevated neutrophil-to-lymphocyte ratio (NLR) is prognostic for worse outcomes in patients with a variety of solid cancers, including those treated with immune checkpoint i...
-
Article
Open AccessTargeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells
Accumulating evidence demonstrates that the Urokinase Receptor (uPAR) regulates tumor cell migration through its assembly in composite regulatory units with transmembrane receptors, and uPAR88–92 is the minimal s...
-
Article
Open AccessWhat have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO)
Treatment strategies that target the immune system provide the opportunity for antitumor activity across multiple cancer types, regardless of mutational status or tumor histology. While many of the initial adv...
-
Article
Open AccessImmunoscore: a new possible approach for melanoma classification
-
Article
Open AccessHigh expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab
-
Article
Open AccessEfficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
Patients with melanoma brain metastases have a poor prognosis and historically have been excluded from clinical trials. The Expanded Access Program (EAP) provided an opportunity to evaluate the feasibility of...
-
Article
Open AccessEfficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
Elderly patients with metastatic melanoma have different disease characteristics and a poorer prognosis than younger patients. Data from clinical trials and expanded access programmes (EAPs) suggest ipilimumab...
-
Article
Open AccessLong-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis
Treatment of early and multiple cutaneous unresectable recurrences is a major therapeutic problem with around 80% of patients relapsing within 5 years. For lesions refractory to elective treatments, electroche...
